Bristol Myers Squibb Reports Positive Phase 3 Results For Admilparant In IPF

Bristol Myers Squibb reported that its experimental radiopharmaceutical therapy, RYZ101, slowed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors. The company acquired RYZ101 through its $4.1 billion takeover of RayzeBio. Shares rose nearly 4% premarket. The late-stage trial tested RYZ101 against standard treatments in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Bristol Myers Squibb announced positive Phase III trial results for admilparant. The drug showed significant improvement in lung function for IPF patients compared to placebo after 52 weeks, meeting its primary endpoint.

Bristol Myers Squibb (BMY) reported two successful Phase 3 trials, one for a lung disease treatment and another for cancer. The company's stock attempted to recover its 200-day moving average, while a rival's shares dropped over 25%. The lung disease study involved the drug admilparant for idiopathic pulmonary fibrosis (IPF).

Bristol Myers Squibb (BMY) shares rose 6.5% after positive Phase 3 trial results for RYZ101 (neuroendocrine tumors) and admilparant (pulmonary fibrosis). Both met primary endpoints, supporting potential regulatory submissions. The company plans FDA discussions for RYZ101 and further analysis for admilparant.

Bristol-Myers Squibb (BMY) reported positive interim results from the ACTION-1 trial of RYZ101, showing improved progression-free survival. The FDA previously granted RYZ101 Orphan Drug Designation. BMY's stock rose 3.57% in pre-market trading.

Bristol Myers Squibb (BMY) reported that its Phase 3 ALOFT-IPF trial for admilparant in idiopathic pulmonary fibrosis met the primary endpoint at the 60 mg dose, showing statistically significant improvement in forced vital capacity (FVC) compared to placebo. The 120 mg dose slowed FVC decline but was not statistically significant. Admilparant showed a well-tolerated safety profile.